BioPharma Dive November 13, 2024
Gwendolyn Wu

The California biotech, which is partnered with Eli Lilly and J&J, plans to use the funds to advance one of its wholly owned drugs for eczema into Phase 1 testing.

Dive Brief:

  • TRex Bio, a California biotechnology company that’s partnered with Eli Lilly and Johnson & Johnson, has raised $84 million in a Series B round meant to advance its immune drug research, the company said Wednesday.
  • The new funds will be used to push the company’s second drug candidate, dubbed TRB-061, into a Phase 1 clinical trial in the first half of next year. The drug is designed to treat atopic dermatitis and ulcerative colitis.
  • The round adds to two milestone payments TRex earned earlier this year from...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
How Agencies Should Decide Which Costly Drugs To Target With Government March-In Rights
Biotech startups are built on venture capital. Track funding rounds here.
Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin
What might a Trump administration mean for the Biosecure Act?

Share This Article